Trials / Completed
CompletedNCT00306293
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | valacyclovir | valacyclovir |
Timeline
- Start date
- 2006-02-20
- Primary completion
- 2006-11-27
- Completion
- 2006-11-27
- First posted
- 2006-03-23
- Last updated
- 2018-03-23
- Results posted
- 2018-03-23
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00306293. Inclusion in this directory is not an endorsement.